EP0880508B1
(en)
|
1996-02-13 |
2003-04-16 |
AstraZeneca AB |
Quinazoline derivatives as vegf inhibitors
|
GB9603095D0
(en)
|
1996-02-14 |
1996-04-10 |
Zeneca Ltd |
Quinazoline derivatives
|
KR100489174B1
(ko)
|
1996-03-05 |
2005-09-30 |
제네카-파마 소시에떼아노님 |
4-아닐리노퀴나졸린유도체
|
GB9707800D0
(en)
|
1996-05-06 |
1997-06-04 |
Zeneca Ltd |
Chemical compounds
|
HRP970371A2
(en)
|
1996-07-13 |
1998-08-31 |
Kathryn Jane Smith |
Heterocyclic compounds
|
GB9718972D0
(en)
|
1996-09-25 |
1997-11-12 |
Zeneca Ltd |
Chemical compounds
|
NZ334125A
(en)
|
1996-09-25 |
2000-10-27 |
Zeneca Ltd |
Quinoline derivatives inhibiting the effect of growth factors such as VEGF
|
DE69838172T2
(de)
|
1997-08-22 |
2008-04-10 |
Astrazeneca Ab |
Oxindolylchinazolinderivate als angiogenesehemmer
|
GB9800569D0
(en)
|
1998-01-12 |
1998-03-11 |
Glaxo Group Ltd |
Heterocyclic compounds
|
US6297258B1
(en)
|
1998-09-29 |
2001-10-02 |
American Cyanamid Company |
Substituted 3-cyanoquinolines
|
CN1144786C
(zh)
|
1998-09-29 |
2004-04-07 |
美国氰胺公司 |
作为蛋白质酪氨酸激酶抑制剂的取代的3-氰基喹啉
|
US6288082B1
(en)
|
1998-09-29 |
2001-09-11 |
American Cyanamid Company |
Substituted 3-cyanoquinolines
|
US7262201B1
(en)
*
|
1998-10-08 |
2007-08-28 |
Astrazeneca Ab |
Quinazoline derivatives
|
JP3270834B2
(ja)
|
1999-01-27 |
2002-04-02 |
ファイザー・プロダクツ・インク |
抗がん剤として有用なヘテロ芳香族二環式誘導体
|
UA71945C2
(en)
*
|
1999-01-27 |
2005-01-17 |
Pfizer Prod Inc |
Substituted bicyclic derivatives being used as anticancer agents
|
SI1154774T1
(en)
|
1999-02-10 |
2005-10-31 |
Astrazeneca Ab |
Quinazoline derivatives as angiogenesis inhibitors
|
GB9904103D0
(en)
|
1999-02-24 |
1999-04-14 |
Zeneca Ltd |
Quinoline derivatives
|
GB9910580D0
(en)
|
1999-05-08 |
1999-07-07 |
Zeneca Ltd |
Chemical compounds
|
GB9910579D0
(en)
|
1999-05-08 |
1999-07-07 |
Zeneca Ltd |
Chemical compounds
|
JP2003503351A
(ja)
|
1999-06-30 |
2003-01-28 |
メルク エンド カムパニー インコーポレーテッド |
Srcキナーゼ阻害化合物
|
AU5636900A
(en)
|
1999-06-30 |
2001-01-31 |
Merck & Co., Inc. |
Src kinase inhibitor compounds
|
US6316444B1
(en)
|
1999-06-30 |
2001-11-13 |
Merck & Co., Inc. |
SRC kinase inhibitor compounds
|
WO2001004111A1
(en)
*
|
1999-07-09 |
2001-01-18 |
Glaxo Group Limited |
Anilinoquinazolines as protein tyrosine kinase inhibitors
|
US6933299B1
(en)
|
1999-07-09 |
2005-08-23 |
Smithkline Beecham Corporation |
Anilinoquinazolines as protein tyrosine kinase inhibitors
|
US6432979B1
(en)
|
1999-08-12 |
2002-08-13 |
American Cyanamid Company |
Method of treating or inhibiting colonic polyps and colorectal cancer
|
PT1244647E
(pt)
|
1999-11-05 |
2006-10-31 |
Astrazeneca Ab |
Derivados de quinazolina como inibidores de vegf
|
UA74803C2
(uk)
|
1999-11-11 |
2006-02-15 |
Осі Фармасьютікалз, Інк. |
Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
|
UA75055C2
(uk)
*
|
1999-11-30 |
2006-03-15 |
Пфайзер Продактс Інк. |
Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
|
US6638929B2
(en)
|
1999-12-29 |
2003-10-28 |
Wyeth |
Tricyclic protein kinase inhibitors
|
GB0002952D0
(en)
*
|
2000-02-09 |
2000-03-29 |
Pharma Mar Sa |
Process for producing kahalalide F compounds
|
UA73993C2
(uk)
|
2000-06-06 |
2005-10-17 |
Астразенека Аб |
Хіназолінові похідні для лікування пухлин та фармацевтична композиція
|
AR031248A1
(es)
*
|
2000-06-30 |
2003-09-17 |
Glaxo Group Ltd |
Compuestos de ditosilato de quinazolina, composicion farmaceutica, metodo de tratamiento y uso en terapia y proceso para la preparacion de dichos compuestos
|
AU2001276536B2
(en)
|
2000-08-09 |
2007-01-04 |
Astrazeneca Ab |
Quinoline derivatives having vegf inhibiting activity
|
KR20080027400A
(ko)
|
2000-08-21 |
2008-03-26 |
아스트라제네카 아베 |
퀴나졸린 유도체
|
US6660731B2
(en)
|
2000-09-15 |
2003-12-09 |
Vertex Pharmaceuticals Incorporated |
Pyrazole compounds useful as protein kinase inhibitors
|
EP1317449B1
(en)
|
2000-09-15 |
2006-05-31 |
Vertex Pharmaceuticals Incorporated |
Pyrazole compounds useful as protein kinase inhibitors
|
US20040044204A1
(en)
*
|
2000-09-20 |
2004-03-04 |
Werner Mederski |
4-amino-quinazolines
|
AU2001293817A1
(en)
*
|
2000-09-20 |
2002-04-02 |
Merck Patent Gmbh |
4-amino-quinazolines
|
AU7622500A
(en)
*
|
2000-09-29 |
2002-07-01 |
Neurogen Corp |
High affinity small molecule c5a receptor modulators
|
WO2002030926A1
(en)
|
2000-10-13 |
2002-04-18 |
Astrazeneca Ab |
Quinazoline derivatives
|
EP1326859A1
(en)
|
2000-10-13 |
2003-07-16 |
AstraZeneca AB |
Quinazoline derivatives with anti-tumour activity
|
DE60137273D1
(de)
|
2000-10-20 |
2009-02-12 |
Eisai R&D Man Co Ltd |
Verfahren zur Herstellung von 4-Phenoxy chinolin Derivaten
|
JP2004514718A
(ja)
|
2000-11-02 |
2004-05-20 |
アストラゼネカ アクチボラグ |
抗癌剤としての置換キノリン類
|
AU2001295791A1
(en)
|
2000-11-02 |
2002-05-15 |
Astrazeneca Ab |
4-substituted quinolines as antitumor agents
|
ATE340172T1
(de)
|
2000-12-21 |
2006-10-15 |
Vertex Pharma |
Pyrazolverbindungen als protein- kinasehemmer
|
MY143465A
(en)
|
2001-01-05 |
2011-05-13 |
Pfizer |
Antibodies to insulin-like growth factor i receptor
|
ATE290882T1
(de)
|
2001-01-16 |
2005-04-15 |
Glaxo Group Ltd |
Pharmazeutische mischung gegen krebs, die ein 4- chinazolinamin in kombination mit paclitaxel, carboplatin or vinorelbine enthält
|
ES2280517T3
(es)
*
|
2001-03-23 |
2007-09-16 |
Bayer Pharmaceuticals Corporation |
Inhibidor de rho-cinasa.
|
PE20021011A1
(es)
*
|
2001-03-23 |
2003-02-01 |
Bayer Corp |
Derivados quinazolinicos como inhibidores de la rho-quinasa
|
US7141577B2
(en)
|
2001-04-19 |
2006-11-28 |
Astrazeneca Ab |
Quinazoline derivatives
|
GB0112836D0
(en)
|
2001-05-25 |
2001-07-18 |
Smithkline Beecham Plc |
Medicaments
|
GB0112834D0
(en)
|
2001-05-25 |
2001-07-18 |
Smithkline Beecham Plc |
Medicaments
|
US6995171B2
(en)
|
2001-06-21 |
2006-02-07 |
Agouron Pharmaceuticals, Inc. |
Bicyclic pyrimidine and pyrimidine derivatives useful as anticancer agents
|
US7829566B2
(en)
*
|
2001-09-17 |
2010-11-09 |
Werner Mederski |
4-amino-quinazolines
|
ATE423104T1
(de)
*
|
2001-11-03 |
2009-03-15 |
Astrazeneca Ab |
Quinazolin derivate als antitumor-mittel
|
GB0126433D0
(en)
*
|
2001-11-03 |
2002-01-02 |
Astrazeneca Ab |
Compounds
|
AR039067A1
(es)
|
2001-11-09 |
2005-02-09 |
Pfizer Prod Inc |
Anticuerpos para cd40
|
AU2002366581A1
(en)
*
|
2001-12-12 |
2003-06-23 |
Pfizer Products Inc. |
Salt forms of E-2-methoxy-N-(3-(4-(3-methyl-pyridin-3-yloxy)-phenylamino)-quinazolin-6-yl)-allyl)-acetamide, its preparation and its use against cancer
|
US6797825B2
(en)
|
2001-12-13 |
2004-09-28 |
Abbott Laboratories |
Protein kinase inhibitors
|
US20030187026A1
(en)
|
2001-12-13 |
2003-10-02 |
Qun Li |
Kinase inhibitors
|
DE60320933D1
(de)
*
|
2002-01-10 |
2008-06-26 |
Bayer Healthcare Ag |
Rho-kinase inhibitoren
|
EA200400816A1
(ru)
*
|
2002-01-17 |
2005-02-24 |
Ньюроджин Корпорейшн |
Замещенные аналоги хиназолин-4-иламина в качестве модуляторов капсаицина
|
MXPA04007191A
(es)
*
|
2002-01-23 |
2005-03-31 |
Bayer Pharmaceuticals Corp |
Derivados de pirimidina como inhibidores de rho-quinasa.
|
EP1470122B1
(en)
*
|
2002-01-23 |
2007-12-19 |
Bayer Pharmaceuticals Corporation |
Rho-kinase inhibitors
|
BR0307151A
(pt)
|
2002-02-01 |
2004-12-07 |
Astrazeneca Ab |
Composto ou um sal do mesmo, processo para a preparação do mesmo, composição farmacêutica, uso do composto ou de um seu sal, método para produzir um efeito antiangiogênico e/ou redutor da permeabilidade vascular em um animal de sangue quente, como um ser humano, que necessita de um tratamento do tipo referido, e, processos para a preparação de 5-bromo-7- azaindol, e para a produção de 5-metóxi-7-azaindol
|
US7645878B2
(en)
*
|
2002-03-22 |
2010-01-12 |
Bayer Healthcare Llc |
Process for preparing quinazoline Rho-kinase inhibitors and intermediates thereof
|
US6924285B2
(en)
|
2002-03-30 |
2005-08-02 |
Boehringer Ingelheim Pharma Gmbh & Co. |
Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
|
JP2005534623A
(ja)
*
|
2002-04-08 |
2005-11-17 |
スミスクライン ビーチャム コーポレーション |
Erbファミリーの阻害剤並びにraf及び/又はras阻害剤を投与することを含む癌の治療法
|
UA77303C2
(en)
|
2002-06-14 |
2006-11-15 |
Pfizer |
Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
|
MY141867A
(en)
|
2002-06-20 |
2010-07-16 |
Vertex Pharma |
Substituted pyrimidines useful as protein kinase inhibitors
|
GB0215823D0
(en)
|
2002-07-09 |
2002-08-14 |
Astrazeneca Ab |
Quinazoline derivatives
|
WO2004004732A1
(en)
|
2002-07-09 |
2004-01-15 |
Astrazeneca Ab |
Quinazoline derivatives for use in the treatment of cancer
|
ES2400339T3
(es)
*
|
2002-07-15 |
2013-04-09 |
Symphony Evolution, Inc. |
Compuestos, composiciones farmacéuticas de los mismos y su uso en el tratamiento del cáncer
|
WO2004011456A1
(en)
*
|
2002-07-31 |
2004-02-05 |
Danter Wayne R |
Protein tyrosine kinase inhibitors
|
ES2273043T3
(es)
|
2002-08-02 |
2007-05-01 |
Vertex Pharmaceuticals Incorporated |
Composiciones de pirazol utiles como inhibidores de gsk-3.
|
ES2298563T3
(es)
*
|
2002-10-09 |
2008-05-16 |
Critical Outcome Technologies, Inc. |
Inhibidores de proteinas tirosina cinasas.
|
GB0304367D0
(en)
*
|
2003-02-26 |
2003-04-02 |
Pharma Mar Sau |
Methods for treating psoriasis
|
GB0225579D0
(en)
|
2002-11-02 |
2002-12-11 |
Astrazeneca Ab |
Chemical compounds
|
US7462623B2
(en)
|
2002-11-04 |
2008-12-09 |
Astrazeneca Ab |
Quinazoline derivatives as Src tyrosine kinase inhibitors
|
US7488823B2
(en)
|
2003-11-10 |
2009-02-10 |
Array Biopharma, Inc. |
Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors
|
WO2004055003A1
(en)
*
|
2002-12-13 |
2004-07-01 |
Neurogen Corporation |
2-substituted quinazolin-4-ylamine analogues as capsaicin receptor modulators
|
MXPA05006676A
(es)
|
2002-12-19 |
2005-08-16 |
Pfizer |
Compuestos de indazol y composiciones farmaceuticas para inhibir proteinquinasas, y procedimientos para su uso.
|
DK1625121T3
(da)
|
2002-12-20 |
2010-05-10 |
Pfizer Prod Inc |
Pyrimidinderivater til behandling af abnorm cellevækst
|
AP2114A
(en)
|
2003-02-26 |
2010-03-04 |
Sugen Inc |
Aminoheteroaryl compounds as protein kinase inhibitors
|
US8013156B2
(en)
|
2003-03-19 |
2011-09-06 |
Exelixis, Inc. |
Tie-2 modulators and methods of use
|
GB0309850D0
(en)
|
2003-04-30 |
2003-06-04 |
Astrazeneca Ab |
Quinazoline derivatives
|
TWI328009B
(en)
|
2003-05-21 |
2010-08-01 |
Glaxo Group Ltd |
Quinoline derivatives as phosphodiesterase inhibitors
|
CN1984660B
(zh)
*
|
2003-07-03 |
2010-12-15 |
美瑞德生物工程公司 |
作为天冬氨酸特异性半胱氨酸蛋白酶活化剂和细胞程序死亡诱导剂的4-芳基氨基-喹唑啉
|
WO2006074147A2
(en)
|
2005-01-03 |
2006-07-13 |
Myriad Genetics, Inc. |
Nitrogen containing bicyclic compounds and therapeutical use thereof
|
US8309562B2
(en)
|
2003-07-03 |
2012-11-13 |
Myrexis, Inc. |
Compounds and therapeutical use thereof
|
AR045037A1
(es)
|
2003-07-10 |
2005-10-12 |
Aventis Pharma Sa |
Tetrahidro-1h-pirazolo [3,4-c] piridinas sustituidas, composiciones que las contienen y su utilizacion.
|
TW200510373A
(en)
*
|
2003-07-14 |
2005-03-16 |
Neurogen Corp |
Substituted quinolin-4-ylamine analogues
|
US7329664B2
(en)
*
|
2003-07-16 |
2008-02-12 |
Neurogen Corporation |
Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues
|
EP1653986A4
(en)
*
|
2003-08-01 |
2007-03-14 |
Smithkline Beecham Corp |
TREATMENT OF CANCERS EXPRESSING P95 SP ERBB2 / SP
|
CN102432552B
(zh)
*
|
2003-08-14 |
2016-01-20 |
阿雷生物药品公司 |
作为受体酪氨酸激酶抑制剂的喹唑啉类似物
|
US7501427B2
(en)
|
2003-08-14 |
2009-03-10 |
Array Biopharma, Inc. |
Quinazoline analogs as receptor tyrosine kinase inhibitors
|
ES2314444T3
(es)
|
2003-08-29 |
2009-03-16 |
Pfizer Inc. |
Tienopiridina-fenilacetaminasy sus derivados utiles como nuevos agentes antiangiogenicos.
|
GB0321066D0
(en)
*
|
2003-09-09 |
2003-10-08 |
Pharma Mar Sau |
New antitumoral compounds
|
AU2004270740A1
(en)
*
|
2003-09-09 |
2005-03-17 |
Neurogen Corporation |
4 - heterobicyclyamino - substituted quinazolines and analogues therof as capsaicin - antagonists
|
AR045563A1
(es)
|
2003-09-10 |
2005-11-02 |
Warner Lambert Co |
Anticuerpos dirigidos a m-csf
|
ES2305844T3
(es)
|
2003-09-16 |
2008-11-01 |
Astrazeneca Ab |
Derivados de quinazolina como inhibidores de tirosina cinasa.
|
GB0322409D0
(en)
|
2003-09-25 |
2003-10-29 |
Astrazeneca Ab |
Quinazoline derivatives
|
PL2210607T3
(pl)
*
|
2003-09-26 |
2012-01-31 |
Exelixis Inc |
N-[3-fluoro-4-({6-(metyloksy)-7-[(3-morfolin-4-ylopropylo)oksy]chinolin-4-ylo} oxy)fenylo]-N'-(4-fluorofenylo)cyklopropano-1,1-dikarboksamid do leczenia raka
|
CN101337930B
(zh)
|
2003-11-11 |
2010-09-08 |
卫材R&D管理有限公司 |
脲衍生物的制备方法
|
US7511065B2
(en)
*
|
2003-11-12 |
2009-03-31 |
Eli Lilly And Company |
Mixed lineage kinase modulators
|
GB0326459D0
(en)
|
2003-11-13 |
2003-12-17 |
Astrazeneca Ab |
Quinazoline derivatives
|
EP1689721B1
(en)
*
|
2003-11-26 |
2010-07-14 |
Pfizer Products Inc. |
Aminopyrazole derivatives as gsk-3 inhibitors
|
GB0330002D0
(en)
|
2003-12-24 |
2004-01-28 |
Astrazeneca Ab |
Quinazoline derivatives
|
CN1914182B
(zh)
|
2004-02-03 |
2011-09-07 |
阿斯利康(瑞典)有限公司 |
喹唑啉衍生物
|
GEP20084551B
(en)
|
2004-05-06 |
2008-11-25 |
Warner Lambert Co |
4-phenylamino-quinazolin-6-yl-amides
|
WO2005120509A1
(en)
*
|
2004-06-04 |
2005-12-22 |
Amphora Discovery Corporation |
Quinoline- and isoquinoline-based compounds exhibiting atp-utilizing enzyme inhibitory activity, and compositions, and uses thereof
|
EP2335727A3
(en)
|
2004-07-16 |
2011-09-28 |
Pfizer Products Inc. |
Combination treatment for non-hematologic malignancies using an anti-IGF-1R antibody
|
EA013678B1
(ru)
|
2004-08-26 |
2010-06-30 |
Пфайзер Инк. |
Энантиомерно чистые аминогетероарильные соединения в качестве ингибиторов протеинкиназы
|
JP2008513463A
(ja)
|
2004-09-15 |
2008-05-01 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
チアゾロピリジンキナーゼ阻害剤
|
JP4834553B2
(ja)
|
2004-09-17 |
2011-12-14 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
医薬組成物
|
US20070054916A1
(en)
*
|
2004-10-01 |
2007-03-08 |
Amgen Inc. |
Aryl nitrogen-containing bicyclic compounds and methods of use
|
TW200621251A
(en)
|
2004-10-12 |
2006-07-01 |
Neurogen Corp |
Substituted biaryl quinolin-4-ylamine analogues
|
US7947676B2
(en)
|
2004-12-14 |
2011-05-24 |
Astrazeneca Ab |
Pyrazolo[3,4-d]pyrimidine compounds as antitumor agents
|
US8258145B2
(en)
|
2005-01-03 |
2012-09-04 |
Myrexis, Inc. |
Method of treating brain cancer
|
US20090155247A1
(en)
*
|
2005-02-18 |
2009-06-18 |
Ashkenazi Avi J |
Methods of Using Death Receptor Agonists and EGFR Inhibitors
|
US20060188498A1
(en)
*
|
2005-02-18 |
2006-08-24 |
Genentech, Inc. |
Methods of using death receptor agonists and EGFR inhibitors
|
JP4137174B2
(ja)
*
|
2005-02-23 |
2008-08-20 |
塩野義製薬株式会社 |
チロシンキナーゼ阻害作用を有するキナゾリン誘導体
|
CA2603093A1
(en)
|
2005-03-31 |
2006-10-05 |
Agensys, Inc. |
Antibodies and related molecules that bind to 161p2f10b proteins
|
EP2444421A1
(en)
|
2005-04-26 |
2012-04-25 |
Pfizer Inc. |
P-Cadherin antibodies
|
GB0508715D0
(en)
*
|
2005-04-29 |
2005-06-08 |
Astrazeneca Ab |
Chemical compounds
|
US7579356B2
(en)
|
2005-05-04 |
2009-08-25 |
Janssen Pharmaceutica Nv |
Thia-tetraazaacenaphthylene kinase inhibitors
|
MX2008001033A
(es)
*
|
2005-07-27 |
2008-03-19 |
Hoffmann La Roche |
Derivados de 4-ariloxi quinolina como moduladores de 5-ht6.
|
EP2281901B1
(en)
|
2005-08-02 |
2013-11-27 |
Eisai R&D Management Co., Ltd. |
Anti-tumour pharmaceutical composition with angiogenesis inhibitors
|
TWI541253B
(zh)
|
2005-09-07 |
2016-07-11 |
艾默根佛蒙特有限公司 |
針對類活化素受體激酶-1之人類單株抗體
|
WO2007033196A1
(en)
*
|
2005-09-14 |
2007-03-22 |
Bristol-Myers Squibb Company |
Met kinase inhibitors
|
AU2006292278B2
(en)
|
2005-09-20 |
2012-03-08 |
Osi Pharmaceuticals, Inc. |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
EP1928861B1
(en)
|
2005-09-20 |
2010-11-17 |
AstraZeneca AB |
4- (ih-indazol-5-yl-amino)-quinazoline compounds as erbb receptor tyrosine kinase inhibitors for the treatment of cancer
|
GB0520475D0
(en)
*
|
2005-10-07 |
2005-11-16 |
Arrow Therapeutics Ltd |
Chemical compounds
|
TW200734327A
(en)
|
2005-11-03 |
2007-09-16 |
Vertex Pharma |
Aminopyrimidines useful as kinase inhibitors
|
PL2090575T3
(pl)
|
2005-11-15 |
2011-09-30 |
Array Biopharma Inc |
Sposoby i związki pośrednie do otrzymywania pochodnych N4-fenylo-chinazolino-4-aminy
|
US20100158863A1
(en)
*
|
2006-01-11 |
2010-06-24 |
Arrow Therapeutics Limited |
Triazoloanilinopyrimidine derivatives for use as antiviral agents
|
DE102006012251A1
(de)
*
|
2006-03-15 |
2007-11-08 |
Grünenthal GmbH |
Substituierte 4-Amino-chinazolin-Derivate und ihre Verwendung zur Herstellung von Arzneimitteln
|
JP4383525B2
(ja)
|
2006-05-09 |
2009-12-16 |
ファイザー・プロダクツ・インク |
シクロアルキルアミノ酸誘導体およびその医薬組成物
|
NL2000613C2
(nl)
|
2006-05-11 |
2007-11-20 |
Pfizer Prod Inc |
Triazoolpyrazinederivaten.
|
EP2036557B1
(en)
|
2006-05-18 |
2015-10-21 |
Eisai R&D Management Co., Ltd. |
Antitumor agent for thyroid cancer
|
WO2008016123A1
(fr)
*
|
2006-08-03 |
2008-02-07 |
Takeda Pharmaceutical Company Limited |
INHIBITEUR DE LA GSK-3β
|
AU2007288204A1
(en)
*
|
2006-08-22 |
2008-02-28 |
Concert Pharmaceuticals Inc. |
4-aminoquinazoline derivatives and methods of use thereof
|
US20110053964A1
(en)
*
|
2006-08-22 |
2011-03-03 |
Roger Tung |
4-aminoquinazoline derivatives and methods of use thereof
|
KR101472600B1
(ko)
|
2006-08-28 |
2014-12-15 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
미분화형 위암에 대한 항종양제
|
ES2372217T3
(es)
|
2006-09-12 |
2012-01-17 |
Genentech, Inc. |
Procedimientos y composiciones para el diagnóstico y tratamiento del cáncer de pulmón utilizando el gen de pdgfra, kit o kdr como marcador genético.
|
KR101129868B1
(ko)
*
|
2006-10-04 |
2012-04-12 |
화이자 프로덕츠 인코포레이티드 |
칼슘 수용체 길항제로서의 피리도[4,3-d]피리미딘-4(3H)-온 유도체
|
MY146474A
(en)
|
2006-11-06 |
2012-08-15 |
Supergen Inc |
Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
|
EP1921070A1
(de)
|
2006-11-10 |
2008-05-14 |
Boehringer Ingelheim Pharma GmbH & Co. KG |
Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
|
US8138191B2
(en)
|
2007-01-11 |
2012-03-20 |
Critical Outcome Technologies Inc. |
Inhibitor compounds and cancer treatment methods
|
US8034815B2
(en)
|
2007-01-11 |
2011-10-11 |
Critical Outcome Technologies, Inc. |
Compounds and method for treatment of cancer
|
US8962655B2
(en)
|
2007-01-29 |
2015-02-24 |
Eisai R&D Management Co., Ltd. |
Composition for treatment of undifferentiated gastric cancer
|
BRPI0807234A2
(pt)
|
2007-02-06 |
2014-06-03 |
Boehringer Ingelheim Int |
Heterociclos bicíclicos, composições farmacêuticas que contêm estes compostos, o uso dos mesmos e processos para a preparação dos mesmos
|
CA2682504C
(en)
|
2007-04-05 |
2012-10-30 |
Amgen Inc. |
Aurora kinase modulators and method of use
|
EP2851091B1
(en)
|
2007-04-13 |
2017-12-27 |
Dana-Farber Cancer Institute, Inc. |
Methods for treating cancer resistant to ERBB therapeutics
|
CA2684447C
(en)
|
2007-04-18 |
2012-01-24 |
Pfizer Products Inc. |
Sulfonyl amide derivatives for the treatment of abnormal cell growth
|
MX2009011810A
(es)
|
2007-05-02 |
2010-01-14 |
Vertex Pharma |
Tiazoles y pirazoles utiles como inhibidores de cinasa.
|
CN101367794B
(zh)
*
|
2007-07-20 |
2013-07-10 |
上海恒瑞医药有限公司 |
喹唑啉类衍生物的制备方法及其在医药上的应用
|
WO2009012647A1
(fr)
*
|
2007-07-20 |
2009-01-29 |
Shanghai Hengrui Pharmaceutical Co., Ltd. |
Procédés de préparation de dérivés de quinazoline et leurs utilisations pharmaceutiques
|
CA2694499A1
(en)
|
2007-07-31 |
2009-02-05 |
Vertex Pharmaceuticals Incorporated |
Process for preparing 5-fluoro-1h-pyrazolo [3, 4-b] pyridin-3-amine and derivatives thereof
|
SG10201500328QA
(en)
|
2007-08-21 |
2015-03-30 |
Amgen Inc |
Human c-fms antigen binding proteins
|
PL2185574T3
(pl)
|
2007-09-07 |
2013-09-30 |
Agensys Inc |
Przeciwciała i powiązane cząsteczki, które wiążą się do białek 24P4C12
|
AU2008312400A1
(en)
*
|
2007-10-19 |
2009-04-23 |
Albert Einstein College Of Medicine Of Yeshiva University |
Improved antitumoral treatments
|
US8080558B2
(en)
|
2007-10-29 |
2011-12-20 |
Natco Pharma Limited |
4-(tetrazol-5-yl)-quinazoline derivatives as anti-cancer agent
|
AU2008325608B2
(en)
|
2007-11-09 |
2013-03-14 |
Eisai R & D Management Co., Ltd. |
Combination of anti-angiogenic substance and anti-tumor platinum complex
|
US20110053991A1
(en)
*
|
2007-11-19 |
2011-03-03 |
Gore Lia |
Treatment of Histone Deacetylase Mediated Disorders
|
WO2009079797A1
(en)
*
|
2007-12-26 |
2009-07-02 |
Critical Outcome Technologies, Inc. |
Compounds and method for treatment of cancer
|
JP2011515330A
(ja)
*
|
2008-01-30 |
2011-05-19 |
ファルマ・マール・ソシエダード・アノニマ |
改良抗腫瘍治療剤
|
TWI472339B
(zh)
|
2008-01-30 |
2015-02-11 |
Genentech Inc |
包含結合至her2結構域ii之抗體及其酸性變異體的組合物
|
DK2245026T3
(da)
|
2008-02-07 |
2012-10-15 |
Boehringer Ingelheim Int |
Spirocycliske heterocycler, lægemiddel indeholdende disse forbindelser, deres anvendelse og fremgangsmåde til deres fremstilling
|
KR20100126479A
(ko)
*
|
2008-03-07 |
2010-12-01 |
파르마 마르 에스.에이. |
개선된 항종양 치료법들
|
JP2011515401A
(ja)
|
2008-03-20 |
2011-05-19 |
アムジエン・インコーポレーテツド |
オーロラキナーゼモジュレーターおよび使用方法
|
US20110182888A1
(en)
*
|
2008-04-08 |
2011-07-28 |
Peter Ordentlich |
Administration of an Inhibitor of HDAC, an Inhibitor of HER-2, and a Selective Estrogen Receptor Modulator
|
WO2009137714A2
(en)
*
|
2008-05-07 |
2009-11-12 |
Teva Pharmaceutical Industries Ltd. |
Forms of lapatinib ditosylate and processes for preparation thereof
|
MX2010012442A
(es)
|
2008-05-13 |
2011-10-11 |
Astrazeneca Ab |
Sal de fumarato de 4-(3-cloro-2-fluoroanilino)-7-metoxi-6-{[1-(n-m etilcarbamoilmetil) piperidin-4-il]oxi}quinazolina.
|
CN101584696A
(zh)
|
2008-05-21 |
2009-11-25 |
上海艾力斯医药科技有限公司 |
包含喹唑啉衍生物的组合物及制备方法、用途
|
US20100197915A1
(en)
*
|
2008-08-06 |
2010-08-05 |
Leonid Metsger |
Lapatinib intermediates
|
US8648191B2
(en)
|
2008-08-08 |
2014-02-11 |
Boehringer Ingelheim International Gmbh |
Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
|
US9126935B2
(en)
|
2008-08-14 |
2015-09-08 |
Amgen Inc. |
Aurora kinase modulators and methods of use
|
US20100087459A1
(en)
*
|
2008-08-26 |
2010-04-08 |
Leonid Metsger |
Forms of lapatinib compounds and processes for the preparation thereof
|
EA201100426A1
(ru)
*
|
2008-09-02 |
2011-10-31 |
Новартис Аг |
Бициклические ингибиторы киназы
|
MX2011002312A
(es)
|
2008-09-03 |
2011-04-26 |
Vertex Pharma |
Co-cristales y formulaciones farmaceuticas que comprenden los mismos.
|
TW201014860A
(en)
|
2008-09-08 |
2010-04-16 |
Boehringer Ingelheim Int |
New chemical compounds
|
JP5836125B2
(ja)
|
2008-10-16 |
2015-12-24 |
ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション |
高分子量メラノーマ関連抗原に対する完全ヒト抗体およびその使用
|
MX2011004824A
(es)
|
2008-11-07 |
2012-01-12 |
Triact Therapeutics Inc |
Uso de derivados de butano catecólico en terapia contra el cáncer.
|
CN102388024A
(zh)
|
2009-01-16 |
2012-03-21 |
埃克塞里艾克西斯公司 |
N-(4-{[6,7-双(甲基氧基)喹啉-4-基]氧基}苯基)-n’-(4-氟苯基)环丙烷-1,1-二甲酰胺的苹果酸盐及其用于癌症治疗的结晶型
|
CN101787017A
(zh)
*
|
2009-01-23 |
2010-07-28 |
岑均达 |
光学纯喹唑啉类化合物
|
SG172857A1
(en)
|
2009-02-09 |
2011-08-29 |
Supergen Inc |
Pyrrolopyrimidinyl axl kinase inhibitors
|
US20120189641A1
(en)
|
2009-02-25 |
2012-07-26 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
EP2400990A2
(en)
|
2009-02-26 |
2012-01-04 |
OSI Pharmaceuticals, LLC |
In situ methods for monitoring the emt status of tumor cells in vivo
|
WO2010099364A2
(en)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
JP2012519281A
(ja)
|
2009-02-27 |
2012-08-23 |
オーエスアイ・ファーマシューティカルズ,エルエルシー |
間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
|
WO2010099138A2
(en)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
US20100222381A1
(en)
|
2009-02-27 |
2010-09-02 |
Hariprasad Vankayalapati |
Cyclopentathiophene/cyclohexathiophene DNA methyltransferase inhibitors
|
WO2010107968A1
(en)
|
2009-03-18 |
2010-09-23 |
Osi Pharmaceuticals, Inc. |
Combination cancer therapy comprising administration of an egfr inhibitor and an igf-1r inhibitor
|
PE20120539A1
(es)
|
2009-03-20 |
2012-05-12 |
Genentech Inc |
Anticuerpos anti-her biespecifico
|
EP2270002A1
(en)
|
2009-06-18 |
2011-01-05 |
Vereniging voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek en Patiëntenzorg |
Quinazoline derivatives as histamine H4-receptor inhibitors for use in the treatment of inflammatory disorders
|
SI2448582T1
(sl)
|
2009-06-29 |
2017-09-29 |
Agios Pharmaceuticals, Inc. |
Derivati kinolin-8-sulfonamida, ki imajo protirakovo aktivnost
|
BRPI1015363A2
(pt)
|
2009-07-02 |
2015-08-25 |
Newgen Therapeutics Inc |
Compostos de quinazolina contendo fósforo, uso dos mesmos, composição e kit
|
UA108618C2
(uk)
|
2009-08-07 |
2015-05-25 |
|
Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
|
DK2467140T3
(en)
|
2009-08-21 |
2016-09-05 |
Novartis Ag |
Lapatinib for the treatment of cancer
|
JP2013503846A
(ja)
|
2009-09-01 |
2013-02-04 |
ファイザー・インク |
ベンズイミダゾール誘導体
|
BR112012008330B1
(pt)
|
2009-09-03 |
2022-03-22 |
Bristol-Myers Squibb Company |
Compostos quinazolinas, suas composições farmacêuticas e seus usos
|
WO2011035540A1
(zh)
|
2009-09-28 |
2011-03-31 |
齐鲁制药有限公司 |
作为酪氨酸激酶抑制剂的4-(取代苯胺基)喹唑啉衍生物
|
CA2780319A1
(en)
|
2009-11-12 |
2011-05-19 |
Genentech, Inc. |
A method of promoting dendritic spine density
|
US20120316187A1
(en)
|
2009-11-13 |
2012-12-13 |
Pangaea Biotech, S.L. |
Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
|
WO2011079231A1
(en)
*
|
2009-12-23 |
2011-06-30 |
Gatekeeper Pharmaceutical, Inc. |
Compounds that modulate egfr activity and methods for treating or preventing conditions therewith
|
CN102108079B
(zh)
*
|
2009-12-25 |
2014-10-01 |
齐鲁制药有限公司 |
作为酪氨酸激酶抑制剂的4-(取代苯胺基)喹唑啉衍生物
|
RU2012132278A
(ru)
|
2010-01-12 |
2014-02-20 |
Ф. Хоффманн-Ля Рош Аг |
Трициклические гетероциклические соединения, содержащие их композиции и способы их применения
|
MX343383B
(es)
|
2010-02-12 |
2016-11-03 |
Pfizer Inc * |
Sales y polimorfos de 8-fluoro-2-{4-[(metilamino)metil]fenil}-1,3, 4,5-tetrahidro-6h-acepino[5,4,3-cd]indol-6-ona.
|
CN102153544B
(zh)
*
|
2010-02-12 |
2015-04-29 |
上海阳帆医药科技有限公司 |
一类酪氨酸激酶抑制剂的制备及用途
|
ES2519348T3
(es)
|
2010-02-18 |
2014-11-06 |
Genentech, Inc. |
Antagonistas de neurregulina y uso de los mismos en el tratamiento del cáncer
|
CA2783665A1
(en)
|
2010-03-03 |
2011-09-09 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
AU2011223643A1
(en)
|
2010-03-03 |
2012-06-28 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
BR112012023382A2
(pt)
|
2010-03-17 |
2018-05-15 |
F Hoffmann La Roche Ag T |
compostos, composições e métodos de uso de imidazopiridina.
|
JP5833626B2
(ja)
*
|
2010-03-23 |
2015-12-16 |
サイノファーム タイワン リミテッド |
ラパチニブの調製プロセス及び中間体
|
CA2999435A1
(en)
|
2010-04-01 |
2011-10-06 |
Critical Outcome Technologies Inc. |
Compounds and method for treatment of hiv
|
MX2012011887A
(es)
|
2010-04-16 |
2012-11-30 |
Genentech Inc |
Foxo 3a como biomarcador predictivo para la eficacia del inhibidor de la via de quinasa pi3k/akt.
|
CN104689314B
(zh)
|
2010-06-16 |
2018-02-02 |
高等教育联邦***-匹兹堡大学 |
内质蛋白的抗体及其用途
|
MX2012014776A
(es)
|
2010-06-25 |
2013-01-29 |
Eisai R&D Man Co Ltd |
Agente antitumoral que emplea compuestos con efecto inhibidor de cinasas combinados.
|
EP2612151B1
(en)
|
2010-08-31 |
2017-08-09 |
Genentech, Inc. |
Biomarkers and methods of treatment
|
EP2616072A1
(en)
|
2010-09-15 |
2013-07-24 |
F.Hoffmann-La Roche Ag |
Azabenzothiazole compounds, compositions and methods of use
|
WO2012052948A1
(en)
|
2010-10-20 |
2012-04-26 |
Pfizer Inc. |
Pyridine- 2- derivatives as smoothened receptor modulators
|
EP2640722B1
(en)
|
2010-11-19 |
2015-11-04 |
F.Hoffmann-La Roche Ag |
Pyrazolopyridines and their use as tyk2 inhibitors
|
CN102552271B
(zh)
*
|
2010-12-09 |
2014-08-06 |
中国科学院上海药物研究所 |
一类喹唑啉类化合物在制备抗黄病毒科病毒的药物中的用途
|
EP2468883A1
(en)
|
2010-12-22 |
2012-06-27 |
Pangaea Biotech S.L. |
Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
|
WO2012085176A1
(en)
|
2010-12-23 |
2012-06-28 |
F. Hoffmann-La Roche Ag |
Tricyclic pyrazinone compounds, compositions and methods of use thereof as janus kinase inhibitors
|
US9134297B2
(en)
|
2011-01-11 |
2015-09-15 |
Icahn School Of Medicine At Mount Sinai |
Method and compositions for treating cancer and related methods
|
US20120214830A1
(en)
|
2011-02-22 |
2012-08-23 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
|
EP2492688A1
(en)
|
2011-02-23 |
2012-08-29 |
Pangaea Biotech, S.A. |
Molecular biomarkers for predicting response to antitumor treatment in lung cancer
|
RU2013144571A
(ru)
|
2011-03-04 |
2015-04-10 |
Ньюджен Терапьютикс, Инк. |
Алинзамещенные хиназолины и способы их применения
|
KR101940340B1
(ko)
|
2011-03-04 |
2019-01-18 |
글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 |
키나제 억제제로서의 아미노-퀴놀린
|
ES2740399T3
(es)
|
2011-03-09 |
2020-02-05 |
Richard G Pestell |
Líneas de células de cáncer de próstata, firmas genéticas y usos de estas
|
WO2012125904A1
(en)
|
2011-03-17 |
2012-09-20 |
The Trustees Of The University Of Pennsylvania |
Mutation mimicking compounds that bind to the kinase domain of egfr
|
US9321759B2
(en)
|
2011-03-17 |
2016-04-26 |
The Trustees Of The University Of Pennsylvania |
Methods and use of bifunctional enzyme-building clamp-shaped molecules
|
WO2012129145A1
(en)
|
2011-03-18 |
2012-09-27 |
OSI Pharmaceuticals, LLC |
Nscle combination therapy
|
WO2012142164A1
(en)
|
2011-04-12 |
2012-10-18 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Human monoclonal antibodies that bind insulin-like growth factor (igf) i and ii
|
RU2580609C2
(ru)
|
2011-04-18 |
2016-04-10 |
Эйсай Ар Энд Ди Менеджмент Ко., Лтд. |
Противоопухолевое терапевтическое средство
|
CA2830972C
(en)
|
2011-04-19 |
2018-11-20 |
Pfizer Inc. |
Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
|
JP2014519813A
(ja)
|
2011-04-25 |
2014-08-21 |
オーエスアイ・ファーマシューティカルズ,エルエルシー |
癌薬剤発見、診断、および治療におけるemt遺伝子シグネチャーの使用
|
WO2012155339A1
(zh)
|
2011-05-17 |
2012-11-22 |
江苏康缘药业股份有限公司 |
4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途
|
ES2705950T3
(es)
|
2011-06-03 |
2019-03-27 |
Eisai R&D Man Co Ltd |
Biomarcadores para predecir y valorar la capacidad de respuesta de sujetos con cáncer de tiroides y de riñón a compuestos de lenvatinib
|
WO2013007765A1
(en)
|
2011-07-13 |
2013-01-17 |
F. Hoffmann-La Roche Ag |
Fused tricyclic compounds for use as inhibitors of janus kinases
|
WO2013007768A1
(en)
|
2011-07-13 |
2013-01-17 |
F. Hoffmann-La Roche Ag |
Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors
|
PT3409278T
(pt)
|
2011-07-21 |
2020-12-18 |
Sumitomo Dainippon Pharma Oncology Inc |
Inibidores de proteína cinase heterocíclicos
|
RU2014105624A
(ru)
|
2011-08-12 |
2015-09-20 |
Ф. Хоффманн-Ля Рош Аг |
Соединения индазола, способ их применения и фармацевтическая композиция
|
MX2014001766A
(es)
|
2011-08-17 |
2014-05-01 |
Genentech Inc |
Anticuerpos de neuregulina y sus usos.
|
TWI547494B
(zh)
|
2011-08-18 |
2016-09-01 |
葛蘭素史克智慧財產發展有限公司 |
作為激酶抑制劑之胺基喹唑啉類
|
MX2014002436A
(es)
|
2011-08-31 |
2014-05-27 |
Genentech Inc |
Marcadores de diagnostico.
|
WO2013041539A1
(en)
|
2011-09-20 |
2013-03-28 |
F. Hoffmann-La Roche Ag |
Imidazopyridine compounds, compositions and methods of use
|
MX2014003501A
(es)
|
2011-09-22 |
2014-07-22 |
Pfizer |
Derivados de pirrolopirimidina y purina.
|
CN104066851A
(zh)
|
2011-09-30 |
2014-09-24 |
基因泰克公司 |
肿瘤或肿瘤细胞中上皮或间充质表型的诊断性甲基化标志物和对egfr激酶抑制剂的响应
|
AU2011378675B2
(en)
|
2011-10-04 |
2017-10-05 |
Epsilogen Ltd |
IgE anti -HMW-MAA antibody
|
WO2013060881A1
(en)
|
2011-10-27 |
2013-05-02 |
Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg |
Pyridopyrimidines and their therapeutic use
|
BR112014011115A2
(pt)
|
2011-11-08 |
2017-06-13 |
Pfizer |
métodos para tratamento de distúrbios inflamatórios usando anticorpos anti-m-csf
|
MX2014006529A
(es)
|
2011-11-30 |
2014-11-25 |
Genentech Inc |
Mutaciones de erbb3 en cancer.
|
CN103172641B
(zh)
|
2011-12-20 |
2014-06-11 |
钱卫 |
杂环胺基烷氧基取代的喹唑啉衍生物及其用途
|
US20150023953A1
(en)
|
2012-01-31 |
2015-01-22 |
Smithkline Beecham (Cork) Limited |
Method of treating cancer
|
AR090263A1
(es)
|
2012-03-08 |
2014-10-29 |
Hoffmann La Roche |
Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
|
AU2013240261A1
(en)
|
2012-03-27 |
2014-09-18 |
Genentech, Inc. |
Diagnosis and treatments relating to HER3 inhibitors
|
AU2013243097A1
(en)
|
2012-04-03 |
2014-10-09 |
Novartis Ag |
Combination products with tyrosine kinase inhibitors and their use
|
WO2013152252A1
(en)
|
2012-04-06 |
2013-10-10 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
AU2013262977A1
(en)
|
2012-05-14 |
2015-01-22 |
Prostagene, Llc |
Using modulators of CCR5 for treating cancer
|
WO2013190089A1
(en)
|
2012-06-21 |
2013-12-27 |
Pangaea Biotech, S.L. |
Molecular biomarkers for predicting outcome in lung cancer
|
AR092529A1
(es)
|
2012-09-13 |
2015-04-22 |
Glaxosmithkline Llc |
Compuesto de aminoquinazolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
|
AR092530A1
(es)
|
2012-09-13 |
2015-04-22 |
Glaxosmithkline Llc |
Compuesto de amino-quinolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
|
EP2909181B1
(en)
|
2012-10-16 |
2017-08-09 |
Tolero Pharmaceuticals, Inc. |
Pkm2 modulators and methods for their use
|
US9260426B2
(en)
|
2012-12-14 |
2016-02-16 |
Arrien Pharmaceuticals Llc |
Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors
|
MX2015004979A
(es)
|
2012-12-21 |
2015-07-17 |
Eisai R&D Man Co Ltd |
Forma amorfa de derivado de quinolina y metodo para su produccion.
|
CA2902132C
(en)
|
2013-02-21 |
2020-09-22 |
Glaxosmithkline Intellectual Property Development Limited |
Quinazolines as kinase inhibitors
|
JP2016509045A
(ja)
|
2013-02-22 |
2016-03-24 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
がんを治療し、薬剤耐性を防止する方法
|
WO2014134202A1
(en)
|
2013-02-26 |
2014-09-04 |
Triact Therapeutics, Inc. |
Cancer therapy
|
US9468681B2
(en)
|
2013-03-01 |
2016-10-18 |
California Institute Of Technology |
Targeted nanoparticles
|
US9925240B2
(en)
|
2013-03-06 |
2018-03-27 |
Genentech, Inc. |
Methods of treating and preventing cancer drug resistance
|
RU2015143517A
(ru)
|
2013-03-13 |
2017-04-19 |
Дженентек, Инк. |
Пиразолсодержащие соединения и их применения
|
KR102334260B1
(ko)
|
2013-03-14 |
2021-12-02 |
스미토모 다이니폰 파마 온콜로지, 인크. |
Jak2 및 alk2 억제제 및 이들의 사용 방법
|
CN105246508A
(zh)
|
2013-03-14 |
2016-01-13 |
基因泰克公司 |
Mek抑制剂化合物与her3/egfr抑制剂化合物的组合及使用方法
|
KR20150127216A
(ko)
|
2013-03-14 |
2015-11-16 |
제넨테크, 인크. |
암의 치료 및 암 약물 내성의 예방 방법
|
US20160143910A1
(en)
|
2013-03-15 |
2016-05-26 |
Constellation Pharmaceuticals, Inc. |
Methods of treating cancer and preventing cancer drug resistance
|
WO2014147246A1
(en)
|
2013-03-21 |
2014-09-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method and pharmaceutical composition for use in the treatment of chronic liver diseases associated with a low hepcidin expression
|
US9206188B2
(en)
|
2013-04-18 |
2015-12-08 |
Arrien Pharmaceuticals Llc |
Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors
|
WO2014185540A1
(en)
|
2013-05-14 |
2014-11-20 |
Eisai R&D Management Co., Ltd. |
Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
|
TW201605896A
(zh)
|
2013-08-30 |
2016-02-16 |
安美基股份有限公司 |
Gitr抗原結合蛋白
|
CN105611933B
(zh)
|
2013-09-05 |
2019-01-25 |
基因泰克公司 |
抗增生性化合物
|
US9381246B2
(en)
|
2013-09-09 |
2016-07-05 |
Triact Therapeutics, Inc. |
Cancer therapy
|
TW201605857A
(zh)
|
2013-10-03 |
2016-02-16 |
赫孚孟拉羅股份公司 |
Cdk8之醫療性抑制劑及其用途
|
US20150104392A1
(en)
|
2013-10-04 |
2015-04-16 |
Aptose Biosciences Inc. |
Compositions, biomarkers and their use in the treatment of cancer
|
EP3057615B1
(en)
|
2013-10-18 |
2021-02-24 |
F.Hoffmann-La Roche Ag |
Anti-rspo antibodies and methods of use
|
CN103554091B
(zh)
*
|
2013-11-05 |
2016-05-18 |
沈阳工业大学 |
喹唑啉衍生物及其制备方法和用途
|
UA115388C2
(uk)
|
2013-11-21 |
2017-10-25 |
Пфайзер Інк. |
2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань
|
JP6483697B2
(ja)
*
|
2013-12-09 |
2019-03-13 |
ユーシービー バイオファルマ エスピーアールエル |
Tnf活性のモジュレーターとしての縮合二環式ヘテロ芳香族誘導体
|
AU2014364587B9
(en)
|
2013-12-17 |
2023-02-16 |
Genentech, Inc. |
Methods of treating cancers using PD-1 axis binding antagonists and taxanes
|
EP3083687A2
(en)
|
2013-12-17 |
2016-10-26 |
F. Hoffmann-La Roche AG |
Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
|
RU2016141385A
(ru)
|
2014-03-24 |
2018-04-28 |
Дженентек, Инк. |
Лечение рака антагонистами с-мет и их корреляция с экспрессией hgf
|
KR20160145624A
(ko)
|
2014-03-31 |
2016-12-20 |
제넨테크, 인크. |
항-ox40 항체 및 사용 방법
|
CA2943834A1
(en)
|
2014-03-31 |
2015-10-08 |
Genentech, Inc. |
Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists
|
WO2015155624A1
(en)
|
2014-04-10 |
2015-10-15 |
Pfizer Inc. |
Dihydropyrrolopyrimidine derivatives
|
US20170027940A1
(en)
|
2014-04-10 |
2017-02-02 |
Stichting Het Nederlands Kanker Instituut |
Method for treating cancer
|
AP2016009530A0
(en)
|
2014-04-30 |
2016-10-31 |
Pfizer |
Cycloalkyl-linked diheterocycle derivatives
|
WO2016001789A1
(en)
|
2014-06-30 |
2016-01-07 |
Pfizer Inc. |
Pyrimidine derivatives as pi3k inhibitors for use in the treatment of cancer
|
JP6811706B2
(ja)
|
2014-07-31 |
2021-01-13 |
ザ ホンコン ユニヴァーシティ オブ サイエンス アンド テクノロジー |
Epha4に対するヒトモノクローナル抗体及びそれらの使用
|
PL3524595T3
(pl)
|
2014-08-28 |
2022-10-31 |
Eisai R&D Management Co., Ltd. |
Pochodna chinoliny o wysokiej czystości i sposób jej wytwarzania
|
EP3189046B1
(en)
|
2014-09-05 |
2020-08-26 |
Genentech, Inc. |
Therapeutic compounds and uses thereof
|
CN107073125A
(zh)
|
2014-09-19 |
2017-08-18 |
基因泰克公司 |
Cbp/ep300和bet抑制剂用于治疗癌症的用途
|
CN107912040B
(zh)
|
2014-10-10 |
2021-04-06 |
基因泰克公司 |
作为组蛋白脱甲基酶抑制剂的吡咯烷酰胺化合物
|
JP2017536347A
(ja)
|
2014-10-17 |
2017-12-07 |
ノバルティス アーゲー |
セリチニブとegfr阻害剤の組合せ
|
BR112017009151A2
(pt)
|
2014-11-03 |
2018-03-06 |
Genentech, Inc. |
ensaios para detectar subgrupos imunológicos de célula t e métodos de uso dos mesmos
|
AU2015343339A1
(en)
|
2014-11-03 |
2017-06-15 |
Genentech, Inc. |
Methods and biomarkers for predicting efficacy and evaluation of an OX40 agonist treatment
|
US20160152720A1
(en)
|
2014-11-06 |
2016-06-02 |
Genentech, Inc. |
Combination therapy comprising ox40 binding agonists and tigit inhibitors
|
MA40940A
(fr)
|
2014-11-10 |
2017-09-19 |
Constellation Pharmaceuticals Inc |
Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
|
EP3218376B1
(en)
|
2014-11-10 |
2019-12-25 |
Genentech, Inc. |
Bromodomain inhibitors and uses thereof
|
MA40943A
(fr)
|
2014-11-10 |
2017-09-19 |
Constellation Pharmaceuticals Inc |
Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
|
CA2967368A1
(en)
|
2014-11-17 |
2016-05-26 |
Genentech, Inc. |
Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
|
WO2016086200A1
(en)
|
2014-11-27 |
2016-06-02 |
Genentech, Inc. |
4,5,6,7-tetrahydro-1 h-pyrazolo[4,3-c]pyridin-3-amine compounds as cbp and/or ep300 inhibitors
|
KR20200091954A
(ko)
|
2014-12-15 |
2020-07-31 |
더 리젠츠 오브 더 유니버시티 오브 미시간 |
Egfr 및 pi3k의 소분자 억제제
|
WO2016097918A1
(en)
|
2014-12-18 |
2016-06-23 |
Pfizer Inc. |
Pyrimidine and triazine derivatives and their use as axl inhibitors
|
RU2710735C2
(ru)
|
2014-12-23 |
2020-01-10 |
Дженентек, Инк. |
Композиции и способы лечения и диагностики резистентного к химиотерапии рака
|
JP6900314B2
(ja)
|
2014-12-24 |
2021-07-07 |
ジェネンテック, インコーポレイテッド |
膀胱癌の治療、診断、及び予後判定方法
|
CN107208138A
(zh)
|
2014-12-30 |
2017-09-26 |
豪夫迈·罗氏有限公司 |
用于癌症预后和治疗的方法和组合物
|
EP3242874B1
(en)
|
2015-01-09 |
2018-10-31 |
Genentech, Inc. |
Pyridazinone derivatives and their use in the treatment of cancer
|
EP3242872B1
(en)
|
2015-01-09 |
2019-07-03 |
Genentech, Inc. |
(piperidin-3-yl)(naphthalen-2-yl)methanone derivatives and related compounds as inhibitors of the histone demethylase kdm2b for the treatment of cancer
|
EP3242875B1
(en)
|
2015-01-09 |
2022-02-23 |
Genentech, Inc. |
4,5-dihydroimidazole derivatives and their use as histone demethylase (kdm2b) inhibitors
|
EP3250571B1
(en)
|
2015-01-29 |
2022-11-30 |
Genentech, Inc. |
Therapeutic compounds and uses thereof
|
EP3250552B1
(en)
|
2015-01-30 |
2019-03-27 |
Genentech, Inc. |
Therapeutic compounds and uses thereof
|
MX2017010474A
(es)
|
2015-02-25 |
2017-11-28 |
Eisai R&D Man Co Ltd |
Metodo para suprimir el amargor de un derivado de quinoleina.
|
MA41598A
(fr)
|
2015-02-25 |
2018-01-02 |
Constellation Pharmaceuticals Inc |
Composés thérapeutiques de pyridazine et leurs utilisations
|
AU2015384801B2
(en)
|
2015-03-04 |
2022-01-06 |
Eisai R&D Management Co., Ltd. |
Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
|
KR20180002653A
(ko)
|
2015-04-07 |
2018-01-08 |
제넨테크, 인크. |
효능작용 활성을 갖는 항원 결합 복합체 및 사용 방법
|
CA2982928A1
(en)
|
2015-04-20 |
2016-10-27 |
Tolero Pharmaceuticals, Inc. |
Predicting response to alvocidib by mitochondrial profiling
|
MX2017013956A
(es)
|
2015-05-01 |
2018-09-05 |
Cocrystal Pharma Inc |
Analogos de nucleosidos para el tratamiento de la familia de virus flaviviridae y cancer.
|
LT3294770T
(lt)
|
2015-05-12 |
2020-12-28 |
F. Hoffmann-La Roche Ag |
Vėžio gydymo ir diagnostikos būdai
|
DK3298021T3
(da)
|
2015-05-18 |
2019-08-05 |
Tolero Pharmaceuticals Inc |
Alvocidib-prodrugs, der har øget biotilgængelighed
|
JP7144935B2
(ja)
|
2015-05-29 |
2022-09-30 |
ジェネンテック, インコーポレイテッド |
癌のための治療方法及び診断方法
|
WO2016200835A1
(en)
|
2015-06-08 |
2016-12-15 |
Genentech, Inc. |
Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists
|
AU2016274585A1
(en)
|
2015-06-08 |
2017-12-14 |
Genentech, Inc. |
Methods of treating cancer using anti-OX40 antibodies
|
MX2017015896A
(es)
|
2015-06-16 |
2018-08-09 |
Eisai R&D Man Co Ltd |
Agente anticancerigeno.
|
WO2016205320A1
(en)
|
2015-06-17 |
2016-12-22 |
Genentech, Inc. |
Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes
|
EP3317323B1
(en)
|
2015-07-01 |
2021-05-26 |
California Institute of Technology |
Cationic mucic acid polymer-based delivery systems
|
WO2017009751A1
(en)
|
2015-07-15 |
2017-01-19 |
Pfizer Inc. |
Pyrimidine derivatives
|
EP3331510A4
(en)
|
2015-08-03 |
2019-04-03 |
Tolero Pharmaceuticals, Inc. |
COMBINATORIAL THERAPIES FOR THE TREATMENT OF CANCER
|
PL3341376T3
(pl)
|
2015-08-26 |
2021-08-02 |
Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) |
Skondensowane związki tricykliczne jako inhibitory kinaz białkowych
|
BR112018006873A2
(pt)
|
2015-10-05 |
2018-11-06 |
The Trustees Of Columbia University In The City Of New York |
ativadores do fluxo autofágico e fosfolipase d e depuração de agregados de proteína incluindo tau e tratamento de proteinopatias
|
SG11201804360XA
(en)
|
2015-12-03 |
2018-06-28 |
Agios Pharmaceuticals Inc |
Mat2a inhibitors for treating mtap null cancer
|
HRP20220227T1
(hr)
|
2015-12-16 |
2022-04-29 |
Genentech, Inc. |
Postupak priprave tricikličnih spojeva inhibitora p13k i postupci upotrebe navedenih spojeva u liječenju raka
|
BR112018011029A2
(pt)
|
2016-01-08 |
2018-11-21 |
Hoffmann La Roche |
métodos para tratar ou atrasar a progressão do câncer e para melhorar a função imune em um indivíduo com câncer, usos de um antagonista de ligação e de um anticorpo biespecífico, composições e kits
|
KR20180119632A
(ko)
|
2016-02-29 |
2018-11-02 |
제넨테크, 인크. |
암에 대한 치료 및 진단 방법
|
CN107141293B
(zh)
|
2016-03-01 |
2022-09-23 |
上海医药集团股份有限公司 |
一种含氮杂环化合物、制备方法、中间体、组合物和应用
|
UA126115C2
(uk)
|
2016-03-08 |
2022-08-17 |
Янссен Байотек, Інк. |
Антитіло до gitr
|
US20170319688A1
(en)
|
2016-04-14 |
2017-11-09 |
Genentech, Inc. |
Anti-rspo3 antibodies and methods of use
|
JP2019515670A
(ja)
|
2016-04-15 |
2019-06-13 |
ジェネンテック, インコーポレイテッド |
がんをモニタリングし治療するための方法
|
EP3443114A1
(en)
|
2016-04-15 |
2019-02-20 |
H. Hoffnabb-La Roche Ag |
Diagnostic and therapeutic methods for cancer
|
CA3019921A1
(en)
|
2016-04-15 |
2017-10-19 |
Genentech, Inc. |
Methods for monitoring and treating cancer
|
JP7014736B2
(ja)
|
2016-05-24 |
2022-02-01 |
ジェネンテック, インコーポレイテッド |
がんの処置のためのピラゾロピリジン誘導体
|
EP4067347A1
(en)
|
2016-05-24 |
2022-10-05 |
Genentech, Inc. |
Heterocyclic inhibitors of cbp/ep300 for the treatment of cancer
|
JP2019527037A
(ja)
|
2016-06-08 |
2019-09-26 |
ジェネンテック, インコーポレイテッド |
がんのための診断及び治療方法
|
EP3494139B1
(en)
|
2016-08-05 |
2022-01-12 |
F. Hoffmann-La Roche AG |
Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
|
WO2018029124A1
(en)
|
2016-08-08 |
2018-02-15 |
F. Hoffmann-La Roche Ag |
Therapeutic and diagnostic methods for cancer
|
CA3038712A1
(en)
|
2016-10-06 |
2018-04-12 |
Genentech, Inc. |
Therapeutic and diagnostic methods for cancer
|
JP2019535250A
(ja)
|
2016-10-29 |
2019-12-12 |
ジェネンテック, インコーポレイテッド |
抗mic抗体及び使用方法
|
US11279694B2
(en)
|
2016-11-18 |
2022-03-22 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Alvocidib prodrugs and their use as protein kinase inhibitors
|
AU2017379847B2
(en)
|
2016-12-19 |
2022-05-26 |
Sumitomo Pharma Oncology, Inc. |
Profiling peptides and methods for sensitivity profiling
|
CN116606261A
(zh)
|
2016-12-22 |
2023-08-18 |
美国安进公司 |
Kras g12c抑制剂及其使用方法
|
MX2019010295A
(es)
|
2017-03-01 |
2019-11-21 |
Genentech Inc |
Métodos de diagnóstico y terapéuticos para el cáncer.
|
CN110505883A
(zh)
|
2017-04-13 |
2019-11-26 |
豪夫迈·罗氏有限公司 |
供治疗癌症的方法中使用的白介素-2免疫缀合物,cd40激动剂,和任选地pd-1轴结合拮抗剂
|
JOP20190272A1
(ar)
|
2017-05-22 |
2019-11-21 |
Amgen Inc |
مثبطات kras g12c وطرق لاستخدامها
|
AU2018304458B2
(en)
|
2017-07-21 |
2021-12-09 |
Foundation Medicine, Inc. |
Therapeutic and diagnostic methods for cancer
|
JP2020530297A
(ja)
|
2017-08-11 |
2020-10-22 |
ジェネンテック, インコーポレイテッド |
抗cd8抗体及びその使用
|
JP7333313B2
(ja)
|
2017-09-01 |
2023-08-24 |
シャンハイ ファーマシューティカルズ ホールディング カンパニー,リミティド |
窒素含有複素環化合物、製造方法、中間体、組成物および使用
|
CN116003405A
(zh)
|
2017-09-08 |
2023-04-25 |
美国安进公司 |
Kras g12c的抑制剂及其使用方法
|
EP3679159A1
(en)
|
2017-09-08 |
2020-07-15 |
H. Hoffnabb-La Roche Ag |
Diagnostic and therapeutic methods for cancer
|
JP7196160B2
(ja)
|
2017-09-12 |
2022-12-26 |
スミトモ ファーマ オンコロジー, インコーポレイテッド |
Mcl-1阻害剤アルボシジブを用いた、bcl-2阻害剤に対して非感受性である癌の治療レジメン
|
US20200237766A1
(en)
|
2017-10-13 |
2020-07-30 |
Tolero Pharmaceuticals, Inc. |
Pkm2 activators in combination with reactive oxygen species for treatment of cancer
|
KR20200075860A
(ko)
|
2017-11-06 |
2020-06-26 |
제넨테크, 인크. |
암의 진단 및 치료 방법
|
WO2019126136A2
(en)
|
2017-12-18 |
2019-06-27 |
Sterngreene, Inc. |
Pyrimidine compounds useful as tyrosine kinase inhibitors
|
TW202000702A
(zh)
|
2018-02-26 |
2020-01-01 |
美商建南德克公司 |
用於抗tigit拮抗劑抗體及抗pd-l1拮抗劑抗體治療之投藥
|
MA52496A
(fr)
|
2018-05-04 |
2021-03-10 |
Amgen Inc |
Inhibiteurs de kras g12c et leurs procédés d'utilisation
|
CA3098574A1
(en)
|
2018-05-04 |
2019-11-07 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
CA3099045A1
(en)
|
2018-05-10 |
2019-11-14 |
Amgen Inc. |
Kras g12c inhibitors for the treatment of cancer
|
JP2021524744A
(ja)
|
2018-05-21 |
2021-09-16 |
ナノストリング テクノロジーズ,インコーポレイティド |
分子遺伝子シグネチャーとその使用方法
|
MA52765A
(fr)
|
2018-06-01 |
2021-04-14 |
Amgen Inc |
Inhibiteurs de kras g12c et leurs procédés d'utilisation
|
EP3802537A1
(en)
|
2018-06-11 |
2021-04-14 |
Amgen Inc. |
Kras g12c inhibitors for treating cancer
|
US11285156B2
(en)
|
2018-06-12 |
2022-03-29 |
Amgen Inc. |
Substituted piperazines as KRAS G12C inhibitors
|
SG11202012446UA
(en)
|
2018-06-23 |
2021-01-28 |
Genentech Inc |
Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor
|
WO2020018789A1
(en)
|
2018-07-18 |
2020-01-23 |
Genentech, Inc. |
Methods of treating lung cancer with a pd-1 axis binding antagonist, an antimetabolite, and a platinum agent
|
US11040038B2
(en)
|
2018-07-26 |
2021-06-22 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Methods for treating diseases associated with abnormal ACVR1 expression and ACVR1 inhibitors for use in the same
|
EP3847154A1
(en)
|
2018-09-03 |
2021-07-14 |
F. Hoffmann-La Roche AG |
Carboxamide and sulfonamide derivatives useful as tead modulators
|
KR20210063330A
(ko)
|
2018-09-19 |
2021-06-01 |
제넨테크, 인크. |
방광암에 대한 치료 및 진단 방법
|
JP2022500638A
(ja)
|
2018-09-21 |
2022-01-04 |
ジェネンテック, インコーポレイテッド |
トリプルネガティブ乳癌のための診断方法
|
EP3860608A1
(en)
|
2018-10-04 |
2021-08-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Egfr inhibitors for treating keratodermas
|
KR20210079311A
(ko)
|
2018-10-18 |
2021-06-29 |
제넨테크, 인크. |
육종성 신장암에 대한 진단과 치료 방법
|
JP2020090482A
(ja)
|
2018-11-16 |
2020-06-11 |
アムジエン・インコーポレーテツド |
Kras g12c阻害剤化合物の重要な中間体の改良合成法
|
EP3883565A1
(en)
|
2018-11-19 |
2021-09-29 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
JP7377679B2
(ja)
|
2018-11-19 |
2023-11-10 |
アムジエン・インコーポレーテツド |
がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法
|
WO2020117988A1
(en)
|
2018-12-04 |
2020-06-11 |
Tolero Pharmaceuticals, Inc. |
Cdk9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
|
US20220081438A1
(en)
|
2018-12-19 |
2022-03-17 |
Array Biopharma Inc. |
Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases
|
EP3898615A1
(en)
|
2018-12-19 |
2021-10-27 |
Array Biopharma, Inc. |
7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer
|
AU2019401495A1
(en)
|
2018-12-20 |
2021-06-24 |
Amgen Inc. |
Heteroaryl amides useful as KIF18A inhibitors
|
AU2019403488A1
(en)
|
2018-12-20 |
2021-06-24 |
Amgen Inc. |
KIF18A inhibitors
|
EP3897852A1
(en)
|
2018-12-20 |
2021-10-27 |
Amgen Inc. |
Kif18a inhibitors
|
WO2020132649A1
(en)
|
2018-12-20 |
2020-06-25 |
Amgen Inc. |
Heteroaryl amides useful as kif18a inhibitors
|
JP2022519649A
(ja)
|
2019-02-08 |
2022-03-24 |
ジェネンテック, インコーポレイテッド |
がんの診断および治療方法
|
WO2020167990A1
(en)
|
2019-02-12 |
2020-08-20 |
Tolero Pharmaceuticals, Inc. |
Formulations comprising heterocyclic protein kinase inhibitors
|
CN113710706A
(zh)
|
2019-02-27 |
2021-11-26 |
豪夫迈·罗氏有限公司 |
用于抗tigit抗体和抗cd20抗体或抗cd38抗体治疗的给药
|
US20220146495A1
(en)
|
2019-02-27 |
2022-05-12 |
Epiaxis Therapeutics Pty Ltd |
Methods and agents for assessing t-cell function and predicting response to therapy
|
SG11202109036WA
(en)
|
2019-03-01 |
2021-09-29 |
Revolution Medicines Inc |
Bicyclic heteroaryl compounds and uses thereof
|
CA3130083A1
(en)
|
2019-03-01 |
2020-09-10 |
Revolution Medicines, Inc. |
Bicyclic heterocyclyl compounds and uses thereof
|
WO2020191326A1
(en)
|
2019-03-20 |
2020-09-24 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Treatment of acute myeloid leukemia (aml) with venetoclax failure
|
JP2022519923A
(ja)
|
2019-03-22 |
2022-03-25 |
スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド |
Pkm2モジュレーターを含む組成物およびそれを使用する処置の方法
|
WO2020223233A1
(en)
|
2019-04-30 |
2020-11-05 |
Genentech, Inc. |
Prognostic and therapeutic methods for colorectal cancer
|
AU2020270376A1
(en)
|
2019-05-03 |
2021-10-07 |
Genentech, Inc. |
Methods of treating cancer with an anti-PD-L1 antibody
|
EP3738593A1
(en)
|
2019-05-14 |
2020-11-18 |
Amgen, Inc |
Dosing of kras inhibitor for treatment of cancers
|
CA3140392A1
(en)
|
2019-05-21 |
2020-11-26 |
Amgen Inc. |
Solid state forms
|
CN112300279A
(zh)
|
2019-07-26 |
2021-02-02 |
上海复宏汉霖生物技术股份有限公司 |
针对抗cd73抗体和变体的方法和组合物
|
CA3147451A1
(en)
|
2019-08-02 |
2021-02-11 |
Amgen Inc. |
Kif18a inhibitors
|
US20220289724A1
(en)
|
2019-08-02 |
2022-09-15 |
Amgen Inc. |
Kif18a inhibitors
|
WO2021026099A1
(en)
|
2019-08-02 |
2021-02-11 |
Amgen Inc. |
Kif18a inhibitors
|
MX2022001302A
(es)
|
2019-08-02 |
2022-03-02 |
Amgen Inc |
Inhibidores de kif18a.
|
PE20221449A1
(es)
|
2019-09-04 |
2022-09-21 |
Genentech Inc |
Agentes de union a cd8 y usos de los mismos
|
CN114555116A
(zh)
|
2019-09-27 |
2022-05-27 |
豪夫迈·罗氏有限公司 |
用于抗tigit和抗pd-l1拮抗剂抗体治疗的给药
|
WO2021081212A1
(en)
|
2019-10-24 |
2021-04-29 |
Amgen Inc. |
Pyridopyrimidine derivatives useful as kras g12c and kras g12d inhibitors in the treatment of cancer
|
WO2021083949A1
(en)
|
2019-10-29 |
2021-05-06 |
F. Hoffmann-La Roche Ag |
Bifunctional compounds for the treatment of cancer
|
KR20220109408A
(ko)
|
2019-11-04 |
2022-08-04 |
레볼루션 메디슨즈, 인크. |
Ras 억제제
|
EP4054720A1
(en)
|
2019-11-04 |
2022-09-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
CN115873067A
(zh)
|
2019-11-04 |
2023-03-31 |
锐新医药公司 |
Ras抑制剂
|
CA3155922A1
(en)
|
2019-11-06 |
2021-05-14 |
Huang Huang |
Diagnostic and therapeutic methods for treatment of hematologic cancers
|
CN112778217B
(zh)
*
|
2019-11-08 |
2024-01-26 |
沈阳化工研究院有限公司 |
一种喹唑啉类化合物及其应用
|
WO2021092115A1
(en)
|
2019-11-08 |
2021-05-14 |
Revolution Medicines, Inc. |
Bicyclic heteroaryl compounds and uses thereof
|
MX2022005775A
(es)
|
2019-11-13 |
2022-06-09 |
Genentech Inc |
Compuestos terapeuticos y metodos de uso.
|
US20230192681A1
(en)
|
2019-11-14 |
2023-06-22 |
Amgen Inc. |
Improved synthesis of kras g12c inhibitor compound
|
MX2022005726A
(es)
|
2019-11-14 |
2022-06-09 |
Amgen Inc |
Sintesis mejorada del compuesto inhibidor de g12c de kras.
|
CN114980976A
(zh)
|
2019-11-27 |
2022-08-30 |
锐新医药公司 |
共价ras抑制剂及其用途
|
CR20230210A
(es)
|
2019-12-13 |
2023-06-14 |
Genentech Inc |
ANTICUERPOS ANTI-LY6G6D Y MÉTODOS DE USO (Divisional 2022-0330)
|
EP4076667A1
(en)
|
2019-12-20 |
2022-10-26 |
Erasca, Inc. |
Tricyclic pyridones and pyrimidones
|
BR112022010086A2
(pt)
|
2020-01-07 |
2022-09-06 |
Revolution Medicines Inc |
Dosagem do inibidor de shp2 e métodos de tratamento de câncer
|
WO2021194481A1
(en)
|
2020-03-24 |
2021-09-30 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
CN115315256A
(zh)
|
2020-01-27 |
2022-11-08 |
基因泰克公司 |
用抗tigit拮抗剂抗体治疗癌症的方法
|
WO2021155006A1
(en)
|
2020-01-31 |
2021-08-05 |
Les Laboratoires Servier Sas |
Inhibitors of cyclin-dependent kinases and uses thereof
|
WO2021177980A1
(en)
|
2020-03-06 |
2021-09-10 |
Genentech, Inc. |
Combination therapy for cancer comprising pd-1 axis binding antagonist and il6 antagonist
|
WO2021202959A1
(en)
|
2020-04-03 |
2021-10-07 |
Genentech, Inc. |
Therapeutic and diagnostic methods for cancer
|
CN115885050A
(zh)
|
2020-04-28 |
2023-03-31 |
基因泰克公司 |
用于非小细胞肺癌免疫疗法的方法和组合物
|
CA3181820A1
(en)
|
2020-06-16 |
2021-12-23 |
Genentech, Inc. |
Methods and compositions for treating triple-negative breast cancer
|
BR112022025801A2
(pt)
|
2020-06-18 |
2023-10-03 |
Hoffmann La Roche |
Métodos para tratar um paciente e para tratar um paciente com escc avançado, kit, anticorpo, uso de um anticorpo e uso de um antagonista de ligação
|
AU2021293228A1
(en)
|
2020-06-18 |
2023-02-09 |
Revolution Medicines, Inc. |
Methods for delaying, preventing, and treating acquired resistance to RAS inhibitors
|
US11787775B2
(en)
|
2020-07-24 |
2023-10-17 |
Genentech, Inc. |
Therapeutic compounds and methods of use
|
CN116568824A
(zh)
|
2020-08-03 |
2023-08-08 |
基因泰克公司 |
淋巴瘤的诊断和治疗方法
|
EP4196612A1
(en)
|
2020-08-12 |
2023-06-21 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
IL301062A
(en)
|
2020-09-03 |
2023-05-01 |
Revolution Medicines Inc |
Use of SOS1 inhibitors to treat malignancies with SHP2 mutations
|
PE20231207A1
(es)
|
2020-09-15 |
2023-08-17 |
Revolution Medicines Inc |
Derivados indolicos como inhibidores de ras en el tratamiento del cancer
|
WO2022066805A1
(en)
|
2020-09-23 |
2022-03-31 |
Erasca, Inc. |
Tricyclic pyridones and pyrimidones
|
IL301547A
(en)
|
2020-10-05 |
2023-05-01 |
Genentech Inc |
Dosage for treatment with bispecific anti-FCRH5/anti-CD3 antibodies
|
US20230107642A1
(en)
|
2020-12-18 |
2023-04-06 |
Erasca, Inc. |
Tricyclic pyridones and pyrimidones
|
IL303965A
(en)
|
2020-12-22 |
2023-08-01 |
Mekanistic Therapeutics Llc |
Transmuted heteroaryl aminobenzyl compounds as EGFR and/or PI3K inhibitors
|
EP4267250A1
(en)
|
2020-12-22 |
2023-11-01 |
Qilu Regor Therapeutics Inc. |
Sos1 inhibitors and uses thereof
|
CR20230382A
(es)
|
2021-02-12 |
2023-09-06 |
Hoffmann La Roche |
Derivados de tetrahidroazepina bicíclicos para el tratamiento del cáncer
|
EP4334324A1
(en)
|
2021-05-05 |
2024-03-13 |
Revolution Medicines, Inc. |
Covalent ras inhibitors and uses thereof
|
PE20240088A1
(es)
|
2021-05-05 |
2024-01-16 |
Revolution Medicines Inc |
Inhibidores de ras
|
AR125787A1
(es)
|
2021-05-05 |
2023-08-16 |
Revolution Medicines Inc |
Inhibidores de ras
|
TW202313633A
(zh)
|
2021-05-25 |
2023-04-01 |
美商伊瑞斯卡公司 |
含硫雜芳族三環kras抑制劑
|
WO2022266206A1
(en)
|
2021-06-16 |
2022-12-22 |
Erasca, Inc. |
Kras inhibitor conjugates
|
TW202321261A
(zh)
|
2021-08-10 |
2023-06-01 |
美商伊瑞斯卡公司 |
選擇性kras抑制劑
|
AR127308A1
(es)
|
2021-10-08 |
2024-01-10 |
Revolution Medicines Inc |
Inhibidores ras
|
TW202332429A
(zh)
|
2021-11-24 |
2023-08-16 |
美商建南德克公司 |
治療性化合物及其使用方法
|
TW202340212A
(zh)
|
2021-11-24 |
2023-10-16 |
美商建南德克公司 |
治療性化合物及其使用方法
|
TW202340214A
(zh)
|
2021-12-17 |
2023-10-16 |
美商健臻公司 |
做為shp2抑制劑之吡唑并吡𠯤化合物
|
EP4227307A1
(en)
|
2022-02-11 |
2023-08-16 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
WO2023172940A1
(en)
|
2022-03-08 |
2023-09-14 |
Revolution Medicines, Inc. |
Methods for treating immune refractory lung cancer
|
WO2023191816A1
(en)
|
2022-04-01 |
2023-10-05 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2023219613A1
(en)
|
2022-05-11 |
2023-11-16 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2023240058A2
(en)
|
2022-06-07 |
2023-12-14 |
Genentech, Inc. |
Prognostic and therapeutic methods for cancer
|
WO2023240263A1
(en)
|
2022-06-10 |
2023-12-14 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
WO2024015897A1
(en)
|
2022-07-13 |
2024-01-18 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2024020432A1
(en)
|
2022-07-19 |
2024-01-25 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2024033389A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydrothiazepine derivatives
|
WO2024033458A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydroazepine derivatives
|
WO2024033457A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydrothiazepine derivatives
|
WO2024033388A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydrothiazepine derivatives
|